IPO - Profile


We are a clinical stage immuno-oncology biopharmaceutical company developing transformative precision T cell therapies to treat multiple types of solid tumors. We are focused on advancing cancer therapies through our pioneering work in the field of tumor evolution and our belief that clonal neoantigens represent the most specific class of cancer cell targets. Our platform enables us to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient’s cancer cells but are absent from healthy tissue.

We refer More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$18.00 9,800,000 Positive High 21.54%

Offering Team

  • Legal counsel
  • Latham & Watkins LLP
  • Auditors

Deal Highlights

Deal Tracker

IPO Dates

Filing 25 Mar, 2021

Offer 31 Mar, 2021

Look Ahead

Lock Up Expiry Oct 01, 2021

IPO Terms

Offer Price $18.00
Offer Size 9M

Market Sentiments

Stock Price